{"product_id":"coo-pestle-analysis","title":"(COO) The Cooper Companies, Inc. PESTLE Analysis Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eYour Shortcut to Market Insight Starts Here\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis The Cooper Companies, Inc. PESTLE Analysis explains the political, economic, social, technological, legal, and environmental forces shaping the company and why they matter for strategy and investment. The page includes a real preview\/sample so you can judge style and depth; purchase the full version to download the complete, ready-to-use report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003ePolitical factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e5-region regulatory footprint\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCooperCompanies sells across 5 regions: the Americas, Europe, the Middle East, Africa, and Asia Pacific, so a rule shift in any big market can hit sales and approvals fast. Medical device rules differ by country, which means more local filings and faster compliance checks; the firm must keep products aligned with multiple health authorities at once. With roughly $4 billion in annual net sales, even small delays in registrations can move revenue timing and margins.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFDA and EU MDR oversight\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe US FDA and EU MDR tightly govern CooperCompanies' contact lenses, fertility tools, and surgical devices, so design controls, clinical evidence, and post-market checks stay high. For a company with FY2025 net sales above $4 billion, even a short approval delay can push launches back and slow revenue. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePublic reimbursement for fertility care\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePublic reimbursement for fertility care is a key demand driver for The Cooper Companies, Inc. In the U.S., 22 states and Washington, D.C. have some infertility insurance mandate, but coverage varies widely, so IVF often still costs patients about $15,000 to $25,000 per cycle. Any policy change that expands or trims coverage can quickly lift or दब down volumes for CooperSurgical.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCross-border trade and tariff exposure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCooperCompanies depends on global plants, suppliers, and distributors, so tariffs and customs checks can lift landed costs and slow delivery. In FY2024, net sales were about $3.9 billion, and even small border frictions can matter when medical products move across multiple regions. Geopolitical tension also raises the risk of supply shifts and higher freight costs.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTariffs can squeeze gross margin.\u003c\/li\u003e\n\u003cli\u003eCustoms delays can extend lead times.\u003c\/li\u003e\n\u003cli\u003eMulti-continent shipping raises risk.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eWomen’s health and myopia policy support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePublic health policy is shifting toward prevention, and that supports The Cooper Companies, Inc. in fertility, contraception, and eye care. In the U.S., the CDC says about 1 in 8 women aged 15-44 have used infertility services, while myopia now affects roughly 30% of the global population, keeping screening demand high.\u003c\/p\u003e\n\u003cp\u003eGovernment-backed education and screening programs can lift use of family planning and myopia-control products, especially where early diagnosis is funded. Preventive care also fits routine lens checks and follow-up treatment, which can support repeat demand.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePrevention policy supports early diagnosis.\u003c\/li\u003e\n\u003cli\u003eScreening programs can expand demand.\u003c\/li\u003e\n\u003cli\u003eFamily planning and myopia care both benefit.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCooper Faces High Regulatory and Policy Risk Across Fertility Markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePolitical risk for The Cooper Companies, Inc. stays high because FDA, EU MDR, and local health rules can delay approvals and shift launch timing across 5 regions. Fertility policy matters too: 22 U.S. states plus Washington, D.C. have some infertility mandate, but coverage gaps still shape demand. Trade rules can also lift costs and slow shipments.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFactor\u003c\/th\u003e\n\u003cth\u003eLatest data\u003c\/th\u003e\n\u003cth\u003eWhy it matters\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulation\u003c\/td\u003e\n\u003ctd\u003e5 regions\u003c\/td\u003e\n\u003ctd\u003eSlows filings\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFertility policy\u003c\/td\u003e\n\u003ctd\u003e22 states + D.C.\u003c\/td\u003e\n\u003ctd\u003eMoves volumes\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eScale\u003c\/td\u003e\n\u003ctd\u003eFY2025 sales above $4B\u003c\/td\u003e\n\u003ctd\u003eSmall delays matter\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eExplores the macro factors shaping The Cooper Companies, Inc. across Political, Economic, Social, Technological, Environmental, and Legal dimensions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eA quick, clear PESTLE snapshot of The Cooper Companies, Inc. that simplifies external risk review and strategic planning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a concise, traceable source list linking Cooper Companies’ market, pricing, and competitive claims to industry reports, filings, and trusted datasets for fast due diligence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eEconomic factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e2-segment demand mix\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCooperVision and CooperSurgical sell into different spend cycles: lenses are recurring, while fertility care is more procedure-led. In FY2025, The Cooper Companies said CooperVision was the larger engine, with CooperSurgical smaller but more tied to provider budgets. That mix helps revenue balance, but slowdowns can still hit elective lens buys and treatment volumes.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUSD, EUR, GBP, and JPY FX risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe Cooper Companies, Inc. sells contact lenses and women's health products worldwide, so USD, EUR, GBP, and JPY swings can change reported sales and margins. A stronger U.S. dollar can cut translated overseas revenue even when local demand holds up. Hedging and local pricing help, but FX still matters in a multi-currency business.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInflation in labor, materials, and freight\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMedical device output depends on specialized lenses, plastics, packaging, and freight, so even a 3% to 4% rise in labor and input costs can lift cost of goods sold fast. U.S. inflation stayed near 3% in 2025, and shipping and wage pressure can still squeeze The Cooper Companies, Inc. if price increases lag. If pricing does not keep pace, gross margin can compress.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eInterest rates and elective procedure spending\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHigher rates can squeeze The Cooper Companies, Inc.'s fertility demand because many treatments are paid out of pocket or financed. With the U.S. fed funds rate still at 5.25% to 5.50% in 2025, clinic loans and patient payment plans stay costly, which can slow elective cycles in price-sensitive markets.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigher borrowing costs can delay treatment.\u003c\/li\u003e\n\u003cli\u003eClinic expansion gets more expensive.\u003c\/li\u003e\n\u003cli\u003ePrice-sensitive demand can soften first.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThat matters because IVF is often a discretionary spend: patients may wait, split cycles, or switch to lower-cost clinics when monthly payments rise. For The Cooper Companies, Inc., the risk is strongest where financing is common and reimbursement is thin.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eHealthcare budget pressure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eWhen economic growth slows, hospitals, clinics, and distributors tighten buying plans, which can delay contact lens orders and fertility clinic upgrades for The Cooper Companies, Inc. In 2025, U.S. fertility care still faced uneven demand as patients stayed price-sensitive, so both lens affordability and clinic utilization remained tied to consumer confidence and provider spend.\u003c\/p\u003e\n\u003cp\u003eReimbursement delays can also stretch cash flow across the channel, especially for clinics that depend on insurer payments before restocking or expanding services. That pressure matters because even small budget cuts can hit recurring lens sales and fertility procedure volumes fast.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBudget cuts delay lens purchases\u003c\/li\u003e\n\u003cli\u003eFertility demand stays price-sensitive\u003c\/li\u003e\n\u003cli\u003eReimbursement delays squeeze cash flow\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRates, FX, and inflation shape Cooper Companies’ FY2025 outlook\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEconomic factors for The Cooper Companies, Inc. stay tied to FX, rates, inflation, and consumer spend. FY2025 U.S. fed funds stayed at 5.25% to 5.50%, U.S. inflation was near 3%, and FX can still trim translated sales across USD, EUR, GBP, and JPY.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFactor\u003c\/th\u003e\n\u003cth\u003eFY2025 hit\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRates\u003c\/td\u003e\n\u003ctd\u003e5.25% to 5.50%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInflation\u003c\/td\u003e\n\u003ctd\u003eNear 3%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003eThe Cooper Companies, Inc. PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact document you’ll receive after purchase—fully formatted and ready to use. It provides a concise PESTLE analysis of The Cooper Companies, Inc., covering political, economic, social, technological, legal, and environmental factors that impact strategy and valuation. No placeholders or teasers—this is the finished, downloadable file. Use it immediately for decision-making or presentation purposes.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Social-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eSociological factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAgeing populations and presbyopia\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGlobal ageing supports The Cooper Companies, Inc.’s vision business: the UN says people aged 65+ will reach about 1.6 billion by 2050, and presbyopia typically starts after age 40. As this pool grows, demand rises for multifocal contact lenses and repeat eye-care visits. Older adults also use more surgical and diagnostic services, which supports recurring revenue.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRising myopia in children\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eChild myopia is rising fast: global prevalence is projected to reach 50% by 2050, and in parts of East Asia it already exceeds 80% among teens. That shift supports stronger demand for The Cooper Companies, Inc.'s daily lenses, specialty lenses, and myopia-management products. Early intervention is now a bigger priority for parents and eye-care clinicians, lifting adoption of treatment at younger ages.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Social-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDelayed parenthood and fertility demand\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePeople are starting families later in many countries; in the U.S., the average age of first-time mothers was about 27.5 years in 2023, up sharply over the past decade. That shift lifts demand for fertility testing, embryo services, and assisted reproduction support, and CooperSurgical is well placed to serve that long-term need.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eHigher awareness of women’s health\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHigher awareness of women’s health is lifting demand for contraception, reproductive care, and gynecologic diagnostics. The WHO says 1 in 6 adults face infertility, and social acceptance of fertility treatment keeps rising, which supports more visits and procedures for The Cooper Companies, Inc.'s surgical and office-based products.\u003c\/p\u003e\n\u003cp\u003eThat wider use matters because better awareness turns more patients into buyers across the care path, from screening to treatment.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e1 in 6 adults face infertility\u003c\/li\u003e\n\u003cli\u003eMore demand for fertility care\u003c\/li\u003e\n\u003cli\u003eSupports surgical and office sales\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePreference for convenient vision correction\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eConsumers keep choosing contact lenses because they want comfort, a cleaner look, and more freedom in daily routines. In 2025, Cooper Companies still benefited from that shift as daily and specialty lenses matched active lives and long screen hours better than glasses-only use.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDaily lenses cut care and hassle.\u003c\/li\u003e\n\u003cli\u003eSpecialty fits support active users.\u003c\/li\u003e\n\u003cli\u003eConvenience stays a key demand driver.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAgeing and infertility trends support Cooper Companies demand\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAgeing, myopia, later parenthood, and higher fertility-care acceptance support The Cooper Companies, Inc. In 2025, the UN put people aged 65+ near 830 million, while the WHO says 1 in 6 adults face infertility. These shifts keep demand high for lenses, diagnostics, and reproductive care.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eDriver\u003c\/th\u003e\n\u003cth\u003eLatest data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAgeing\u003c\/td\u003e\n\u003ctd\u003e65+ near 830m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInfertility\u003c\/td\u003e\n\u003ctd\u003e1 in 6 adults\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMyopia\u003c\/td\u003e\n\u003ctd\u003eRising in youth\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Technological-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eTechnological factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced lens designs in 3 formats\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCooperVision’s spherical, toric, and multifocal lenses depend on tight materials science and optical engineering, because each design fixes different vision needs by age and eye condition. In FY2025, CooperCompanies reported about $4.0 billion in net sales, and innovation in lens fit and comfort stays central to growth. New lens designs matter because even small changes in geometry can affect clarity and wear time.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMyopia-control and specialty lens R\u0026amp;D\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMyopia control is moving fast: global myopia is projected to reach 4.9 billion people by 2050, so Cooper Companies must keep lens R\u0026amp;D moving quickly to protect premium share.\u003c\/p\u003e\n\u003cp\u003eIn FY2025, Cooper Companies generated about $4.0 billion in revenue, and that scale supports steady work on specialty lenses for dry eye and eye fatigue, where small material gains can lift adoption.\u003c\/p\u003e\n\u003cp\u003eFaster clinical testing, better comfort, and cleaner fit can decide wins in contact lenses, since premium categories depend on new data, not just brand strength.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Technological-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGenetic testing and embryo screening tools\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCooperSurgical’s embryo screening and fertility consumables rely on high-precision lab tech, data analysis, and strict quality control to assess all 23 chromosome pairs, including 24-chromosome aneuploidy checks. Better accuracy and faster workflow can lift clinic adoption, especially as IVF demand rises and labs seek fewer errors. For The Cooper Companies, Inc., this supports higher-value recurring sales in a market tied to fertility care.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eAutomation in manufacturing and labs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eFor The Cooper Companies, Inc., automation in high-volume manufacturing helps keep product quality, lot traceability, and regulatory records tight, which matters in a market where FDA medical device recalls still run in the hundreds each year. It can also lift yield and cut defects in contact lens and lens-care production.\u003c\/p\u003e\n\u003cp\u003eIn fertility labs, automated embryo culture and imaging systems improve standardization and can raise throughput while reducing operator-to-operator variation.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLess scrap and rework\u003c\/li\u003e\n\u003cli\u003eStronger traceability\u003c\/li\u003e\n\u003cli\u003eMore lab throughput\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eDigital workflows and remote access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eDigital workflows are now central for The Cooper Companies, Inc. Clinics use online ordering, stock tools, and patient systems to cut delays and mistakes. In FY2025, The Cooper Companies reported about $3.9 billion in revenue, and faster data capture helps protect that scale by improving service coordination across eye care and fertility channels.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDigital ordering speeds clinic replenishment\u003c\/li\u003e\n\u003cli\u003eTelehealth supports patient journeys\u003c\/li\u003e\n\u003cli\u003eConnectivity improves data capture\u003c\/li\u003e\n\u003cli\u003eService coordination becomes tighter\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCooper’s Tech Edge: Innovation in Lenses, Fertility, and Digital Care\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTechnological factors matter most for The Cooper Companies, Inc. in contact lens R\u0026amp;D, fertility lab automation, and digital clinic workflows. FY2025 net sales were about $4.0 billion, so even small gains in fit, comfort, yield, and lab speed can move results. Myopia could hit 4.9 billion people by 2050, keeping lens innovation urgent.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eFY2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet sales\u003c\/td\u003e\n\u003ctd\u003e$4.0B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMyopia by 2050\u003c\/td\u003e\n\u003ctd\u003e4.9B people\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Legal-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eLegal factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFDA, CE, and country registrations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe Cooper Companies sells medical devices in more than 100 countries, so FDA clearance, CE marking, and local registrations can all delay launches. Its fiscal 2025 net sales were about $3.9 billion, making even a short approval slip a real revenue risk. The company must keep technical files, quality records, and country filings current, because missed renewals can block sales fast.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHIPAA and GDPR data controls\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe Cooper Companies, Inc. handles fertility and genetic data that can expose health, identity, and family details. HIPAA can penalize covered data lapses up to about $2.1 million per year per violation tier, and GDPR fines can reach €20 million or 4% of global turnover, so storage, transfer, and consent controls are a material legal risk.\u003c\/p\u003e\n\u003cp\u003eAny breach can trigger investigations, claims, and lost trust, which matters in a business built on sensitive patient data. Strong access limits, encryption, and audit trails are not optional; they are core to The Cooper Companies, Inc. risk control.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Legal-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProduct liability and recall risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eWith fiscal 2024 revenue of about $3.92B, even one recall can hit The Cooper Companies, Inc. hard. Contact lenses, surgical devices, and fertility products can trigger claims if a defect or performance issue hurts patients or causes failed outcomes.\u003c\/p\u003e\n\u003cp\u003eThe company has to track adverse events fast and act on corrective steps quickly, because delays can raise legal exposure and regulator scrutiny.\u003c\/p\u003e\n\u003cp\u003eRecalls also cost money and can dent trust with clinicians and patients, which matters in a business built on repeat use and clinical confidence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePatent protection for devices and methods\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCooperCompanies’ lenses, contraceptives, and fertility tools rely on patents and trade secrets to block copycats and keep premium pricing. In the U.S., a patent can run for 20 years from filing, which helps protect long product cycles and R\u0026amp;D payback.\u003c\/p\u003e\n\u003cp\u003eThat IP moat matters most in higher-margin lines, where even one protected design or method can shape years of sales.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e20-year patent term supports long life cycles\u003c\/li\u003e\n\u003cli\u003eTrade secrets protect process know-how\u003c\/li\u003e\n\u003cli\u003eStrong IP helps defend pricing power\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eAnti-bribery and healthcare marketing rules\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eMedical device sales depend on tight controls around doctors and hospitals, and The Cooper Companies, Inc. must track gifts, travel, speaker fees, and promotional claims market by market. Anti-bribery laws like the FCPA can trigger fines of up to $2 million per company per violation, so training and written approvals matter. \u003c\/p\u003e\n\u003cp\u003eIn FY2025, The Cooper Companies, Inc. used its global scale to raise compliance risk, not lower it. The safest response is frequent audits, local-law review, and clean records for every healthcare interaction. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eStrict rules on HCP contact\u003c\/li\u003e\n\u003cli\u003eFCPA penalties can hit $2M\u003c\/li\u003e\n\u003cli\u003eLocal ad rules differ by country\u003c\/li\u003e\n\u003cli\u003eAudit trails cut enforcement risk\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLegal Risk Could Quickly Pressure Cooper’s $3.9B Sales Base\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLegal risk for The Cooper Companies, Inc. centers on product approvals, patient data, and device claims. FY2025 net sales were about $3.9B, so even a short filing or recall delay can hit sales fast.\u003c\/p\u003e\n\u003cp\u003eHIPAA penalties can reach about $2.1M a year per tier, and GDPR fines can reach €20M or 4% of global turnover. Patent protection lasts 20 years from filing, so IP control supports pricing and R\u0026amp;D payback.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eLegal factor\u003c\/th\u003e\n\u003cth\u003eKey data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory filings\u003c\/td\u003e\n\u003ctd\u003e100+ countries\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFY2025 net sales\u003c\/td\u003e\n\u003ctd\u003e~$3.9B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHIPAA fine cap\u003c\/td\u003e\n\u003ctd\u003e~$2.1M\/year\/tier\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGDPR fine cap\u003c\/td\u003e\n\u003ctd\u003e€20M or 4%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatent term\u003c\/td\u003e\n\u003ctd\u003e20 years\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Enviromental-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eEnvironmental factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSingle-use plastics and packaging waste\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSingle-use plastics are a real issue for The Cooper Companies, Inc.: contact lenses are replaced monthly or daily, and global medical packaging adds more waste. UNEP says the world generates about 400 million metric tons of plastic waste a year, so regulators and customers are pushing harder for recyclable materials and less packaging. For a device maker with recurring consumables, waste cuts can affect buying decisions and compliance costs. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEnergy use in cleanrooms and labs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe Cooper Companies, Inc.'s device plants and fertility labs run on 24\/7 cleanroom HVAC, filtration, and lab equipment, so power use is a direct cost driver. In regulated manufacturing, HVAC can account for a large share of site energy demand, and even small efficiency gains cut utility bills and Scope 2 emissions. Lower kWh use also helps protect margins when electricity prices rise.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Enviromental-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eWater and chemical usage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe Cooper Companies, Inc. uses controlled water and chemical inputs in manufacturing and lab work, so strict handling and disposal rules matter. Efficient use cuts waste, supports permit compliance, and lowers spill risk. With tighter ESG reporting and cleaner-process pressure in 2025, even small reductions can help trim operating and remediation costs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eClimate risk to global supply chains\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eClimate risk can hit The Cooper Companies, Inc.’s supply chain through flooded ports, storm-hit freight routes, and supplier shutdowns. With about 80% of global trade moving by sea, even short delays can disrupt medical product flow, so resilient routing, buffer inventory, and dual sourcing matter.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eStorms delay ports and freight\u003c\/li\u003e\n\u003cli\u003eGlobal sourcing raises exposure\u003c\/li\u003e\n\u003cli\u003eRedundant logistics protect supply\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eESG pressure on emissions reduction\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCustomers, investors, and regulators now watch Scope 1 and 2 emissions closely, and that pressure matters for The Cooper Companies, Inc. as it sells into a healthcare market where ESG is part of vendor review. Medical device peers are being pushed to cut energy use, clean up sourcing, and lower transport emissions, because better carbon control can protect access to hospital and distributor contracts.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eScope 1 and 2 data now shape bids.\u003c\/li\u003e\n\u003cli\u003eCleaner supply chains support market access.\u003c\/li\u003e\n\u003cli\u003eLower emissions can lift brand trust.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCooper Faces Rising Environmental Pressure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEnvironmental pressure on The Cooper Companies, Inc. is rising from plastic waste, energy use, and climate risk. UNEP estimates about 400 million metric tons of plastic waste a year, while cleanroom HVAC and 24\/7 lab power lift Scope 2 costs. Storms and port delays can also disrupt global medical supply flow.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFactor\u003c\/th\u003e\n\u003cth\u003eLatest data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePlastic waste\u003c\/td\u003e\n\u003ctd\u003e~400m tons\/year\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEnergy use\u003c\/td\u003e\n\u003ctd\u003e24\/7 HVAC load\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClimate risk\u003c\/td\u003e\n\u003ctd\u003eSea trade ~80%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57191720681737,"sku":"coo-pestle-analysis","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/coo-pestle-analysis.webp?v=1783677454","url":"https:\/\/dcfanalyst.com\/products\/coo-pestle-analysis","provider":"DCF Analyst","version":"1.0","type":"link"}